New York, NYNCT05583708Now EnrollingIRB Ready

Merkel Cell Cancer Clinical Trial in New York, NY

Access cutting-edge merkel cell cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Weill Medical College of Cornell University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions...

Expert Care in New York

Access merkel cell cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related merkel cell cancer treatment provided free

Apply for This New York Location

Check if you qualify for this merkel cell cancer clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Merkel Cell Cancer Study in New York

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma. Pembrolizumab works by helping patient's immune system to fight cancer. Lutathera works by killing cancer cells. Pembrolizumab is approved by the FDA to treat Merkel cell cancer and has caused some Merkel cell cancers to shrink and/or resolve. Lutathera is FDA-approved to trea

Sponsor: Weill Medical College of Cornell University

Who Can Participate

Inclusion Criteria

Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Male and female, age ≥ 18 years at the time of consent. 3. ECOG Performance Status of 0-1 within 28 days prior to registration. 4. Histological or cytological evidence of Merkel cell cancer per AJCC, 8th edition. 5. Presence of somatostatin receptors by Ga-68 dotatate (or equivalent) imaging, which is a requirement for PRRT (lutetium Lu 177 dotatate \[Lutathera®\]). Must have at least one measurable lesion per RECIST 1.1. 6. Must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:
Has received at least 2 doses of an approved anti-PD-1/L1 mAb
Has demonstrated dise

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05583708) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Merkel Cell Cancer Treatment Options in New York, NY

If you're searching for merkel cell cancer treatment options in New York, NY, this clinical trial (NCT05583708) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced merkel cell cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all merkel cell cancer clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in New York, NY

See all myalgic encephalomyelitis clinical trials recruiting in New York — not just this study.

Browse Myalgic Encephalomyelitis Trials in New York →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY